Danske Bank A S Decreases Stock Holdings in Becton, Dickinson and Company $BDX

Danske Bank A S lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 17.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 228,234 shares of the medical instruments supplier’s stock after selling 47,003 shares during the quarter. Danske Bank A S owned about 0.08% of Becton, Dickinson and Company worth $34,539,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in BDX. Imprint Wealth LLC purchased a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $25,000. SHP Wealth Management purchased a new stake in Becton, Dickinson and Company during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc acquired a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. WPG Advisers LLC grew its holdings in Becton, Dickinson and Company by 64.2% in the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 61 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter worth $32,000. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 11,779 shares of company stock worth $1,974,669. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $187.82 on Thursday. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.96. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The firm has a market cap of $51.75 billion, a price-to-earnings ratio of 56.57, a PEG ratio of 12.74 and a beta of 0.19. The firm’s fifty day moving average is $159.86 and its two-hundred day moving average is $161.02.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company’s revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

Wall Street Analyst Weigh In

BDX has been the subject of a number of recent analyst reports. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research report on Monday, July 6th. Piper Sandler increased their price objective on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Bank of America lowered their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Finally, The Goldman Sachs Group lowered their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $185.67.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.